When ischemic stroke patients do not receive intravelous alteplase to help dissolve clots, their odds of survival are significantly reduced, according to a study published in the American Journal of ...

Patients with minor acute ischemic strokes and deficits that are not clearly disabling at presentation do not derive a benefit from IV alteplase, according to results of the PRISMS trial, which was ...

Outcomes after stroke thrombectomy were not better with tissue plasminogen activator (tPA) withheld, according to the MR CLEAN-NO IV trial. Of more than 500 acute stroke patients with large vessel ...

DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute ...

Patients 80 years of age or older who received intravenous tissue plasminogen activator (IV tPA) for acute ischemic stroke had double the mortality rate compared with those who were untreated, a study ...

Please provide your email address to receive an email when new articles are posted on . At 90 days after minor nondisabling acute ischemic stroke, there was no difference in functional outcomes ...

Patients with acute stroke benefit from thrombolysis with IV tissue plasminogen activator (tPA). In the last decade, a number of endovascular techniques have increasingly been used to open blood ...

Please provide your email address to receive an email when new articles are posted on . Patients with minor nondisabling acute ischemic stroke who were treated with alteplase vs. aspirin did not ...

Ischemic stroke patients who do not receive intravelous (IV) alteplase, a clot-dissolving medication, are significantly less likely to survive, according to researchers. Ischemic stroke patients who ...

In patients with acute ischemic stroke, endovascular therapy does not provide better outcomes than systemic intravenous (IV) thrombolysis, despite being more effective at opening obstructed vessels, ...

Honolulu, Hawaii — A new trial shows outcomes with endovascular revascularization are not superior to those achieved with intravenous (IV) thrombolysis in the treatment of acute ischemic stroke. The ...

A major international analysis of 2,313 patients, median age 71, found that giving an IV clot-busting drug before mechanical clot removal modestly increases brain-bleeding risk compared with ...